Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy B London

Showing results (51-60 of 230) with videos related to

Pageof 23
Sort By:
The Journal of Experimental Medicine|July 31, 2020
Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitorsTing Tao, Hui Shi, Meng Wang, et al.
Pediatric Blood & Cancer|May 31, 2020
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectVeronica Moroz, David Machin, Barbara Hero, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|December 5, 2013
Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaborationChaim Kirby, Peter F Ambros, David Billiter, et al.
Blood Advances|December 28, 2023
Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapyMichelle L Schoettler, Leslie Lehmann, Pei-Chi Kao, et al.
Pediatric Blood & Cancer|October 14, 2014
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group reportTanya M Trippett, Cindy L Schwartz, R Paul Guillerman, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer|October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology GroupHoward M Katzenstein, Kay W Chang, Mark Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
Pediatric Blood & Cancer|March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplificationValerie Combaret, Michael D Hogarty, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Pageof 23

Showing results (51-60 of 230) with videos related to

Sort By:
Pageof 23
The Journal of Experimental Medicine|July 31, 2020
Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitorsTing Tao, Hui Shi, Meng Wang, et al.
Pediatric Blood & Cancer|May 31, 2020
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectVeronica Moroz, David Machin, Barbara Hero, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|December 5, 2013
Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaborationChaim Kirby, Peter F Ambros, David Billiter, et al.
Blood Advances|December 28, 2023
Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapyMichelle L Schoettler, Leslie Lehmann, Pei-Chi Kao, et al.
Pediatric Blood & Cancer|October 14, 2014
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group reportTanya M Trippett, Cindy L Schwartz, R Paul Guillerman, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer|October 9, 2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology GroupHoward M Katzenstein, Kay W Chang, Mark Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
Pediatric Blood & Cancer|March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplificationValerie Combaret, Michael D Hogarty, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Pageof 23